Jubilant Life Sciences Limited

213602

Annual Report 2015-16 1

Contents

28
68
94
100
102
104
148
152
154
156
200
20302
04 07 03 2

Board of Directors

Chairman

Director

Executive Director

Director

Director

Co-Chairman

& Managing Director

Annual Report 2015-16 3

Senior Leadership Team

4

Chairman

Co-Chairman & Managing Director

Chairmen's Message

Annual Report 2015-16 5

Dear Fellow Shareholders,

Business Objectives

We are present across

the entire Pharmaceutical ecosystem and see ourselves as a one- stop-shop in the global

Pharmaceutical and Life

Sciences industry.

Performance Review

Chairmen's Message

6

Dividend

Outlook

Shyam S Bhartia

Hari S Bhartia

Annual Report 2015-16

Management Discussion &

Analysis

8

Cautionary Statement

Key Economic and Industry Trends

Our Business Strategy

Strength in North America -

Diversified Low Risk Business Model -

Strategic Client Relationship -

In Pharmaceuticals,

we have a unique US led business model, supplemented with leadership positions in our niche focus areas, which makes us standout amongst

Indian pharmaceutical

companies.

Annual Report 2015-16 9

Management Discussion & Analysis

Financials

Consolidated Income Statement

million)FY 2015FY 2016

Income from Operations

425

Total Income

Depreciation and Amortisation

Items884

481
805

Revenue

on-year at ` to `` `` 412 and Amortisation (EBITDA) year to ` to `` at ``

Finance Cost and Depreciation

10 `` 1

Indebtedness

Review of Operations

(i)

Generics,

(ii) Specialty Pharmaceuticals (Sterile Products), (i)

Specialty Intermediates and Nutritional Products

(ii)

Life Science Chemicals

Segment wise Revenue (` Mn)FY 15FY16YoY

A.Pharmaceuticals26,82030,54814%53%

i)Generics13,98914,4103%25% 68118
ii)Specialty Pharmaceuticals (Sterile Products)12,83216,13826%28%

B.Life Science Ingredients31,44227,475-13%47%

i)Specialty Intermediates and Nutritional Products16,64515,493-7%27% ii)Life Science Chemicals14,79711,983-19%21%

Total Revenue58,26258,0230%100%

Annual Report 2015-16 11

Generics

Active Pharmaceutical Ingredients (APIs)

Solid Dosage Formulations

Jubilant Life Sciences

is an aspiring global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and specialty pharmaceuticals.

Management Discussion & Analysis

12

India Branded Pharmaceuticals (IBP)

Specialty Pharmaceuticals

(Sterile Products)

CMO of Sterile Injectables

Annual Report 2015-16 13

Radiopharmaceuticals

Allergy Therapy Products

Drug Discovery Solutions

Management Discussion & Analysis

14 to L IFE S

CIENCE

I

NGREDIENTS

S

EGMENT

Specialty Intermediates

Our Specialty

Intermediates business

deals in more than 60 commercial products viz. Pyridines, Picolines,

Cyanopyridines and their

value added derivatives (Fine Ingredients & Crop

Science Ingredients),

having applications in pharmaceutical, agrochemical, personal care, and many other life science industries globally.

Annual Report 2015-16 15

Nutritional Products

Life Science Chemicals

M

Management Discussion & Analysis

16 ESS E

NABLERS

Research & Development and

Intellectual Property

Manufacturing

Annual Report 2015-16

Jubilant is committed to

improving the health and quality of people's lives worldwide. Maintaining high and uniform quality standards across our facilities, with emphasis on compliance to regulations, GXP's (Good

Practices) and continuous

improvement.

Management Discussion & Analysis

18

Supply Chain

Human Resource Management

Inspire Confidence, Nurture

Annual Report 2015-16 19

Innovation, Always Stretch, and Excellent Quality. I

NTERNAL

C

ONTROL

S

YSTEMS

Annual Report 2015-16 1

Contents

28
68
94
100
102
104
148
152
154
156
200
20302
04 07 03 2

Board of Directors

Chairman

Director

Executive Director

Director

Director

Co-Chairman

& Managing Director

Annual Report 2015-16 3

Senior Leadership Team

4

Chairman

Co-Chairman & Managing Director

Chairmen's Message

Annual Report 2015-16 5

Dear Fellow Shareholders,

Business Objectives

We are present across

the entire Pharmaceutical ecosystem and see ourselves as a one- stop-shop in the global

Pharmaceutical and Life

Sciences industry.

Performance Review

Chairmen's Message

6

Dividend

Outlook

Shyam S Bhartia

Hari S Bhartia

Annual Report 2015-16

Management Discussion &

Analysis

8

Cautionary Statement

Key Economic and Industry Trends

Our Business Strategy

Strength in North America -

Diversified Low Risk Business Model -

Strategic Client Relationship -

In Pharmaceuticals,

we have a unique US led business model, supplemented with leadership positions in our niche focus areas, which makes us standout amongst

Indian pharmaceutical

companies.

Annual Report 2015-16 9

Management Discussion & Analysis

Financials

Consolidated Income Statement

million)FY 2015FY 2016

Income from Operations

425

Total Income

Depreciation and Amortisation

Items884

481
805

Revenue

on-year at ` to `` `` 412 and Amortisation (EBITDA) year to ` to `` at ``

Finance Cost and Depreciation

10 `` 1

Indebtedness

Review of Operations

(i)

Generics,

(ii) Specialty Pharmaceuticals (Sterile Products), (i)

Specialty Intermediates and Nutritional Products

(ii)

Life Science Chemicals

Segment wise Revenue (` Mn)FY 15FY16YoY

A.Pharmaceuticals26,82030,54814%53%

i)Generics13,98914,4103%25% 68118
ii)Specialty Pharmaceuticals (Sterile Products)12,83216,13826%28%

B.Life Science Ingredients31,44227,475-13%47%

i)Specialty Intermediates and Nutritional Products16,64515,493-7%27% ii)Life Science Chemicals14,79711,983-19%21%

Total Revenue58,26258,0230%100%

Annual Report 2015-16 11

Generics

Active Pharmaceutical Ingredients (APIs)

Solid Dosage Formulations

Jubilant Life Sciences

is an aspiring global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and specialty pharmaceuticals.

Management Discussion & Analysis

12

India Branded Pharmaceuticals (IBP)

Specialty Pharmaceuticals

(Sterile Products)

CMO of Sterile Injectables

Annual Report 2015-16 13

Radiopharmaceuticals

Allergy Therapy Products

Drug Discovery Solutions

Management Discussion & Analysis

14 to L IFE S

CIENCE

I

NGREDIENTS

S

EGMENT

Specialty Intermediates

Our Specialty

Intermediates business

deals in more than 60 commercial products viz. Pyridines, Picolines,

Cyanopyridines and their

value added derivatives (Fine Ingredients & Crop

Science Ingredients),

having applications in pharmaceutical, agrochemical, personal care, and many other life science industries globally.

Annual Report 2015-16 15

Nutritional Products

Life Science Chemicals

M

Management Discussion & Analysis

16 ESS E

NABLERS

Research & Development and

Intellectual Property

Manufacturing

Annual Report 2015-16

Jubilant is committed to

improving the health and quality of people's lives worldwide. Maintaining high and uniform quality standards across our facilities, with emphasis on compliance to regulations, GXP's (Good

Practices) and continuous

improvement.

Management Discussion & Analysis

18

Supply Chain

Human Resource Management

Inspire Confidence, Nurture

Annual Report 2015-16 19

Innovation, Always Stretch, and Excellent Quality. I

NTERNAL

C

ONTROL

S

YSTEMS